{"id":"opc-1085el","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL4742102","moleculeType":"Unknown","molecularWeight":"421.59"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The drug acts as a partial agonist at the 5-HT2C receptor, which is expressed on pro-opiomelanocortin (POMC) neurons in the hypothalamus. Activation of these neurons suppresses appetite and increases energy expenditure, leading to reduced caloric intake and body weight reduction. This mechanism is distinct from monoamine reuptake inhibitors and targets a specific pathway involved in appetite regulation.","oneSentence":"OPC-1085EL is a selective serotonin 5-HT2C receptor agonist that promotes weight loss by increasing satiety and reducing appetite.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:50:37.616Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Obesity or overweight with weight-related comorbidities"}]},"trialDetails":[{"nctId":"NCT05583474","phase":"PHASE3","title":"OPC-1085EL in the Treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Chinese Subjects","status":"COMPLETED","sponsor":"Otsuka Beijing Research Institute","startDate":"2022-09-27","conditions":"Open Angle Glaucoma or Ocular Hypertension","enrollment":204},{"nctId":"NCT02105285","phase":"PHASE3","title":"Efficacy and Safety Study of OPC-1085EL Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2014-04","conditions":"Glaucoma, Ocular Hypertension","enrollment":193},{"nctId":"NCT02105272","phase":"PHASE3","title":"Efficacy and Safety Study of OPC-1085EL Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2014-04","conditions":"Glaucoma, Ocular Hypertension","enrollment":237},{"nctId":"NCT02108288","phase":"PHASE1","title":"Pharmacokinetic Study of OPC-1085EL Ophthalmic Solution in Healthy Male Adult Volunteers","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2014-04","conditions":"Glaucoma, Ocular Hypertension","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["OPC-1085EL ophthalmic solution"],"phase":"phase_3","status":"active","brandName":"OPC-1085EL","genericName":"OPC-1085EL","companyName":"Otsuka Beijing Research Institute","companyId":"otsuka-beijing-research-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"OPC-1085EL is a selective serotonin 5-HT2C receptor agonist that promotes weight loss by increasing satiety and reducing appetite. Used for Obesity or overweight with weight-related comorbidities.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}